Synt:em Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Synt:em General Information
Description
Developer of drugs for the treatment of central nervous system (CNS) disorders. The company is a biopharmaceutical business focused on the discovery and development of new drug candidates for CNS diseases. The company re-engineers therapeutic molecules using peptides, as a means of delivering them to the brain.
Contact Information
Corporate Office
- Parc Scientifique
- Cedex 1, Georges Besse
- 30035 Nimes
- France
Corporate Office
- Parc Scientifique
- Cedex 1, Georges Besse
- 30035 Nimes
- France
Synt:em Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 01-Jan-2005 | Completed | Generating Revenue | |||
| 8. Merger/Acquisition | 03-Nov-2004 | Cancelled | ||||
| 7. Later Stage VC | 09-Jan-2002 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 07-Mar-2001 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 17-Nov-1999 | Completed | Startup | |||
| 4. Early Stage VC | 07-Jan-1998 | Completed | Startup | |||
| 3. Early Stage VC | 01-Dec-1997 | Completed | Startup | |||
| 2. Early Stage VC | 01-Jun-1997 | $347K | $810K | Completed | Startup | |
| 1. Early Stage VC | $462K | $462K | Completed | Startup |
Synt:em Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Synt:em Patents
Synt:em Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-2865735-B1 | Inhibitors of angiogenesis, compositions containing same and use thereof for the treatment of diseases associated with deregulation of angiogenesis | Inactive | 02-Feb-2004 | ||
| AU-2005210063-A1 | Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation | Inactive | 02-Feb-2004 | ||
| US-20070161553-A1 | Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation | Inactive | 02-Feb-2004 | ||
| JP-2008505848-A | Angiogenesis inhibitors, compositions containing them and their use in the treatment of diseases associated with angiogenesis disorders | Pending | 02-Feb-2004 | ||
| FR-2865736-B1 | Inhibitors of angiogenesis, compositions containing same and use thereof for the treatment of diseases associated with deregulation of angiogenesis | Inactive | 02-Feb-2004 | C07K14/4703 |
Synt:em Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | ||
| Banexi Ventures Partners | Venture Capital | Minority | ||
| BankInvest Group | Asset Manager | Minority | ||
| Lombard Odier | Asset Manager | Minority | ||
| Rendex Partners | Venture Capital | Minority |
Synt:em FAQs
-
When was Synt:em founded?
Synt:em was founded in 1995.
-
Where is Synt:em headquartered?
Synt:em is headquartered in Nimes, France.
-
What industry is Synt:em in?
Synt:em’s primary industry is Drug Discovery.
-
Is Synt:em a private or public company?
Synt:em is a Private company.
-
What is Synt:em’s current revenue?
The current revenue for Synt:em is .
-
How much funding has Synt:em raised over time?
Synt:em has raised $33.3M.
-
Who are Synt:em’s investors?
3i Group, Banexi Ventures Partners, BankInvest Group, Lombard Odier, and Rendex Partners are 5 of 10 investors who have invested in Synt:em.
-
When was Synt:em acquired?
Synt:em was acquired on 01-Jan-2005.
-
Who acquired Synt:em?
Synt:em was acquired by CLL Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
